nach oben

Erschienen in:

01.10.2006 | Original Article

Multilayered Epithelium May Be Found in Patients With Barrett’s Epithelium and Dysplasia or Adenocarcinoma

verfasst von: Melissa P. Upton, Norman S. Nishioka, Bernard J. Ransil, Stanley J. Rosenberg, William P. Puricelli, Felice R. Zwas, Helen M. Shields

Erschienen in: Digestive Diseases and Sciences | Ausgabe 10/2006

Einloggen, um Zugang zu erhalten

Abstract

To determine if multilayered epithelium (MLE) is a useful prognostic indicator for a benign natural history of Barrett’s epithelium, we evaluated endoscopic biopsies from patients with Barrett’s epithelium without and with dysplasia and/or adenocarcinoma and from non-Barrett's controls for the presence of MLE. MLE was found in 6% of non-Barrett's controls, 30% of Barrett’s patients with no dysplasia, and 14% of Barrett's patients with dysplasia and/or adenocarcinoma. MLE was significantly associated with shorter lengths of Barrett’s epithelium in both Barrett’s groups. Three of 5 photodynamic therapy patients were noted to develop MLE after therapy. MLE may be found in patients with dysplasia and/or adenocarcinoma and after photodynamic therapy; its presence is not useful as a prognostic indicator for a more benign course of Barrett’s. This study confirms that MLE is significantly associated with shorter lengths of Barrett’s epithelium.

Spechler SJ, Goyal RK (1996) The columnar lined esophagus, intestinal metaplasia and Norman Barrett. Gastroenterology 110:614–621PubMedCrossRef

Falk GW (2002) Barrett’s esophagus. Gastroenterology 122:1569–1591CrossRef

Vaezi MF, Singh S, Richter JE (1995) Role of acid and duodenogastric reflux in esophageal mucosal injury: A review of animal and human studies. Gastroenterology 108:1897–1907PubMedCrossRef

Menges M, Muller M, Zeitz M (2001) Increased acid and bile reflux in Barrett’s esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. Am J Gastroenterol 96:331–337PubMedCrossRef

Triadafilopoulos G (2001) Acid and bile reflux in Barrett’s esophagus: A tale of two evils. Gastroenterology 121:1502–1506PubMed

Winters C Jr, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker III, JF, Johnson DA, Cruess DF, Cotelingam JD, Gurney MS, Cattau EL Jr (1987) Barrett’s esophagus. A prevalent occult complication of gastroesophageal reflux disease. Gastroenterology 92:118–124PubMed

Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR (1993) Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 104:510–513PubMed

Cameron AJ, Lomboy CT, Pera M, Carpenter HA (1995) Adenocarcinoma of the esophagogastric junction and Barrett’s esophagus. Gastroenterology 109:1541–1546PubMedCrossRef

O’Connor JB, Falk GW, Richter JE (1999) The incidence of adenocarcinoma and dysplasia in Barrett’s Esophagus: Report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 94:2037–2042PubMed

10.

Drewitz DJ, Sampliner RE, Garewal HS (1997) The incidence of adenocarcinoma in Barrett’s esophagus: A prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 92:212–221PubMed

11.

Provenzale D, Schmitt C, Wong JB (1999) Barrett’s esophagus: A new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 94:2043–2053PubMedCrossRef

12.

Lagergren J, Bergstrom R, Lindgren A, Nyren O (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340:825–831PubMedCrossRef

13.

Shaheen N, Ransohoff DF (2002) Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: Scientific review. JAMA 287:1972–1981PubMedCrossRef

14.

Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS (2000) Is there publication bias in the reporting of cancer risk in Barrett’s esophagus? Gastroenterology 119:333–338PubMedCrossRef

15.

Peters FTM, Ganesh S, Kuipers EJ, Sluiter WJ, Klinkenberg-Knol EC, Lamers CBHW, Kleibeuker JH (1999) Endoscopic regression of Barrett’s oesophagus during omeprazole treatment: A randomized double blind study. Gut 45:489–494PubMedCrossRef

16.

Ye W, Chow WH, Lagergren J, Yin L, Nyren O (2001) Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux disease and after antireflux surgery. Gastroenterology 121:1286–1293PubMedCrossRef

17.

Carlson N, Lechago J, Richter J, Sampliner RE, Peterson L, Santella RM, Goldblum JR, Falk GW, Ertan A, Younes M (2002) Acid suppression therapy may not alter malignant progression in Barrett’s metaplasia showing p53 protein accumulation. Am J Gastroenterol 97:1340–1345PubMedCrossRef

18.

Katzka DA (2002) Barrett’s esophagus: Surveillance and treatment. Gastroenterol Clin North Am 31:481–497PubMedCrossRef

19.

McDonald ML, Trastek VF, Allen MS (1996) Barrett’s esophagus: Does an antireflux procedure reduce the need for endoscopic surveillance? J Thorac Cardiovasc Surg 111:1135–1140PubMedCrossRef

20.

Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F, Raufman JP, Sampliner R, Schnell T, Sontag S, Vlahcevic ZR, Young R, Williford W (2001) Long term outcome of medical and surgical therapies for gastroesophageal reflux disease: Followup of a randomized controlled trial. JAMA 285:2331–2338PubMedCrossRef

21.

Parrilla P, Martinez de Haro LF, Ortiz A, Munitiz V, Molina J, Bermejo J, Canteras M (2003) Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett’s esophagus. Ann Surg 237:291–298PubMedCrossRef

22.

Cohen S, Parkman HP (1999) Heartburn: A serious symptom.N Engl J Med 340:878–879PubMedCrossRef

23.

Fitzgerald RC, Lascar R, Triadafilopoulos G (2001) Barrett’s oesophagus, dysplasia and pharmacologic acid suppression. Aliment Pharmacol Ther 15:269–276PubMedCrossRef

24.

Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, Geboes K, Casson AG, Kerr D, Young LS (1999) Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 154:965–973PubMed

25.

Bremner CG, Lynch VP, Ellis FJ Jr (1970) Barrett’s esophagus: Congenital or acquired? An experimental study of esophageal mucosal regeneration in the dog. Surgery 68:209–216PubMed

26.

Gillen P, Keeling P, Byrne PJ, West AB, Hennessy TPJ (1988) Experimental columnar metaplasia in the canine oesophagus. Br J Surg 75:113–115PubMed

27.

Li H, Walsh TN, O’Dowd G, Gillen P, Byrne PJ, Hennessy TPJ (1994) Mechanisms of columnar metaplasia and squamous regeneration in experimental Barrett's esophagus. Surgery 115:176–181PubMed

28.

Sbarbati A, Faccioli N, Ricci F, Merigo F, Benati D, Castaldini G, Cordiano C, Osculati F (2002) Ultrastructural phenotype of “intestinal-type” cells in columnar-lined esophagus. Ultrastruct Pathol 26:107–111PubMedCrossRef

29.

Shields, HM, Zwas F, Antonioli DA, Doos WG, Kim S, Spechler SJ (1993) Detection by scanning electron microscopy of a distinctive esophageal surface cell at the junction of squamous and Barrett’s epithelium. Dig Dis Sci 38:97–108PubMedCrossRef

30.

Boch JA, Shields HM, Antonioli DA, Zwas F, Sawhney RA, Trier JS (1997) Distribution of cytokeratin markers in Barrett’s specialized columnar epithelium. Gastroenterology 112:760–765PubMedCrossRef

31.

Glickman JN, Chen Y, Wang HH, Antonioli DA, Odze RD (2001) Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett’s esophagus. Am J Surg Pathol 25:569–578PubMedCrossRef

32.

Glickman JN, Yang A, Shahsafaei A, McKeon F, Odze RD (2001) Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol 32:1157–1165PubMedCrossRef

33.

Shields HM, Rosenberg SJ, Zwas FR, Ransil BJ, Lembo AJ, Odze R (2001) Prospective evaluation of multilayered epithelium in Barrett’s esophagus. Am J Gastroenterol 96:3268–3273PubMedCrossRef

34.

Menke-Pluymers MBE, Hop WCJ, Dees J, Van Blankenstein M, Tilanus HW (1993) Risk factors for the development of an adenocarcinoma in the columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group Cancer 72:1155–1158PubMedCrossRef

35.

Rudolph RE, Vaughan TL, Storer BE, Haggitt RC, Rabinovitch PS, Levine DS, Reid BJ (2000) Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 132:612–620

36.

Iftikhar SY, James PD, Steele RJC, Hardcastle JD, Atkinson M (1992) Length of Barrett’s oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 33:1155–1158PubMed

37.

Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RKH (1999) Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: Prevalence and clinical data. Gastroenterology 116:277–285PubMedCrossRef

38.

Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC, Sommers SC, Yardley JH (1983) Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical applications. Hum Pathol 14:931–968PubMedCrossRef

39.

Reid BJ, Haggitt RC, Rubin CE, Roth G, Surawicz CM, Van Belle G, Lewin K, Weinstein WM, Antonioli DA, Goldman H, MacDonald W, Owen D (1988) Observer variation in the diagnosis of dysplasia in Barrett’s esophagus. Hum Pathol 19:166–178PubMedCrossRef

40.

Spechler SJ (1999) The role of gastric carditis in metaplasia and neoplasia at the gastroesophageal junction. Gastroenterology 117:218–228PubMedCrossRef

41.

Hayashi GM, Haggitt RC (2001) The histology of Barrett’s esophagus: Metaplasia and dysplasia. In: P Sharma, RE Sampliner (eds) Barrett’s esophagus and esophageal adenocarcinoma. Blackwell Science, London, pp. 80–88

42.

Kerneis S, Pringault E (1999) Plasticity of the gastrointestinal epithelium: The M cell paradigm and opportunism of pathogenic microorganisms. Semin Immunol 11:205–215PubMedCrossRef

43.

Takubo K, Arai T, Sawabe M, Miyashita M, Sasajima K, Iwakiri K, Mafune K (2003) Structures of the normal esophagus and Barrett’s esophagus. Esophagus 1:37–47CrossRef

44.

Takubo K (1981) Squamous metaplasia with reserve cell hyperplasia in the esophagogastric junction zone. Acta Pathol Jpn 31:349–359

45.

Takubo K, Tsuchiya S, Fukushi K, Shirota A, Mitomo Y (1981) Dysplasia and reserve cell hyperplasia—like change in the human esophagus. Arch Pathol Jpn 31:999–1013

46.

Su Y, Chen X, Klein M, Fang M, Wang S, Yang CS, Goyal RK (2004) Phenotype of columnar-lined esophagus in rats with esophagogastroduodenal anastomosis: similarity to human Barrett’s esophagus. Lab Invest 84:753–765PubMedCrossRef

47.

Fass R, Hell RW, Garewal HS, Martinez P, Pulliam G, Wendel C, Sampliner RE (2001) Correlation of oesophageal acid exposure with Barrett’s oesophagus length. Gut 48:310–313PubMedCrossRef

48.

Wong DJ, Paulson TG, Prevo LJ, Galipeau PC, Longton G, Blount PL, Reid BJ (2001) P16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett’s metaplastic epithelium. Cancer Res 61:8284–8289PubMed

49.

Sampliner RE (2002) The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol 97:1888–1895PubMedCrossRef

50.

Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q (1998) Photodynamic therapy. J Natl Cancer Inst 90:889–905PubMedCrossRef

51.

Wolfsen HC, Woodward TA, Raimondo M (2002) Photodynamic therapy for dysplastic Barrett’s esophagus and early esophageal adenocarcinoma. Mayo Clin Proc 77:1176–1181PubMedCrossRef

52.

Hur C, Nishioka NS, Gazelle GS (2003) Cost-effectiveness of photodynamic therapy for treatment of Barrett’s esophagus with high grade dysplasia. Dig Dis Sci 48:1273–1283PubMedCrossRef

53.

Overholt BF, Panjehpour M, Halberg DL (2003) Photodynamic therapy for Barrett’s esophagus with dysplasia and/or early stage carcinoma: Long term results. Gastrointest Endosc 58:183–188PubMedCrossRef

54.

Barr H (2001) The role of ablation in the management of high-grade dysplasia. In: HW Tilanus, SEA Attwood (eds) Barrett’s esophagus. Kluwer Academic Publishers, The Netherlands, pp. 259–272

55.

Biddlestone LR, Barham CP, Wilkinson SP, Barr H, Shepherd NA (1998) The histopathology of treated Barrett’s esophagus: Squamous reepithelization after acid suppression and laser and photodynamic therapy. Am J Surg Pathol 22:239–245PubMedCrossRef

56.

Berenson MM, Johnson TD, Markowitz NR, Buchi KN, Samowitz WS (1993) Restoration of squamous mucosa after ablation of Barrett’s esophageal epithelium. Gastroenterology 104:1686–1691PubMed

57.

Wieczorek TJ, Wang HH, Antonioli DA, Glickman JN, Odze RD (2003) Pathologic features of reflux and Helicobacter pylori-associated carditis: A comparative study. Am J Surg Pathol 27:960–968PubMedCrossRef

58.

Glickman JN, Fox V, Antonioli DA, Wang HH, Odze RD (2002) Morphology of the cardia and significance of carditis in pediatric patients. Am J Surg Pathol 26:1032–1039PubMedCrossRef

Titel: Multilayered Epithelium May Be Found in Patients With Barrett’s Epithelium and Dysplasia or Adenocarcinoma
verfasst von: Melissa P. Upton
Norman S. Nishioka
Bernard J. Ransil
Stanley J. Rosenberg
William P. Puricelli
Felice R. Zwas
Helen M. Shields
Publikationsdatum: 01.10.2006
Verlag: Kluwer Academic Publishers-Plenum Publishers
Erschienen in: Digestive Diseases and Sciences / Ausgabe 10/2006
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-006-9243-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2006

Peripheral Neurological Disturbances, Autonomic Dysfunction, and Antineuronal Antibodies in Adult Celiac Disease Before and After a Gluten-Free Diet

Neuroimmune Link in the Mucosa of Chronic Gastritis with Helicobacter pylori Infection

Taurine Ameliorates Water Avoidance Stress–Induced Degenerations of Gastrointestinal Tract and Liver

Sirolimus Monotherapy Versus Sirolimus in Combination with Steroids and/or MMF for Immunosuppression After Liver Transplantation

Predictors of Cirrhosis in Hispanic Patients with Nonalcoholic Steatohepatitis